In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy

• Published in: Drug design, development and therapy Vol. 13; pp. 2043 - 2055
• Main Authors: Shao, Yanping, Luo, Wenda, Guo, Qunyi, Li, Xiaohong, Zhang, Qianqian, Li, Jing
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2019; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Acids; Acute myelocytic leukemia; Acute myeloid leukemia; Analysis; Animals; Anthracyclines; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - chemistry; Antibiotics, Antineoplastic - pharmacology; Apoptosis; Biocompatibility; Biomedical materials; Cancer therapies; Cancer treatment; Cell Proliferation - drug effects; Chemotherapy; Chronic myeloid leukemia; Core-shell structure; Cytotoxicity; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - chemistry; Doxorubicin - pharmacology; Drug Delivery Systems; Drug Liberation; Drug resistance; Drug Resistance, Neoplasm - drug effects; Drug Screening Assays, Antitumor; Drugs; Gallic acid; Gallic Acid - administration & dosage; Gallic Acid - chemistry; Gallic Acid - pharmacology; Health aspects; Hematology; HL-60 Cells; Hospitals; Humans; Hyaluronic acid; Hyaluronic Acid - administration & dosage; Hyaluronic Acid - chemistry; Hyaluronic Acid - pharmacology; Hybrid systems; In vivo methods and tests; Injections, Intravenous; K562 Cells; Laboratory animals; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - pathology; Ligands; lipid-polymer hybrid nanoparticles; Lipids; Lipids - chemistry; Lung cancer; Mice; Mice, Inbred BALB C; Mice, Nude; Microbial drug resistance; Molecular weight; multidrug resistance; Myeloid leukemia; Nanoparticles; Nanoparticles - chemistry; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - metabolism; Neoplasms, Experimental - pathology; Original Research; Particle Size; Phenols (Class of compounds); Polyethylene glycol; Polymers; Polymers - chemistry; Promyeloid leukemia; Surface Properties; Synergistic effect; Therapy; Toxicity; Tumors; China; United States > US; multidrug resistance; doxorubicin; lipid-polymer hybrid nanoparticles; acute myeloid leukemia; gallic acid
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/DDDT.S202818

To investigate the hyaluronic acid (HA) modified, doxorubicin (DOX) and gallic acid (GA) co-delivered lipid-polymeric hybrid nano-system for leukemia therapy. We produced a kind of lipid-polymer hybrid nanoparticle (LPHN) with a core-shell structure in which DOX and GA were co-loaded. In vitro and in vivo leukemia therapeutic effects of the HA modified, DOX and GA co-delivered LPHNs (HA-DOX/GA-LPHNs) were evaluated in DOX resistant human HL-60 promyelocytic leukemia cells (HL-60/ADR cells), DOX resistant human K562 chronic myeloid leukemia cells (K562/ADR cells), and HL-60/ADR cells bearing mouse model. The sizes and zeta potentials of HA modified LPHNs were about 160 nm and -40 mV. HA-DOX/GA-LPHNs showed the most prominent cytotoxicity and the best synergistic effect was obtained when DOX/GA ratio was 2/1. In vivo studies revealed that HA-DOX/GA-LPHNs inhibited tumor growth from 956 mm to 213 mm , with an inhibition rate of 77.7%. In summary, the study showed that HA-DOX/GA-LPHNs can be applied as a promising leukemia therapy system.